Feasibility of sentinel lymph node mapping of the ovary: a systematic review

Federica Dell'Orto, Pim Laven, Martina Delle Marchette, Sandrina Lambrechts, Roy Kruitwagen, Alessandro Buda*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Citations (Web of Science)
2 Downloads (Pure)

Abstract

Pelvic and para-aortic lymphadenectomy is routinely performed in early ovarian cancer to define the stage of the disease. However, it may be associated with increased blood loss, operative time, and length of hospitalization. The sentinel lymph node technique has been shown to be safe and feasible in vulvar, uterine, and cervical cancer. Data detailing feasibility and outcomes of sentinel lymph node mapping in ovarian cancer are scarce. To summarize the studies evaluating the feasibility of sentinel lymph node detection from the ovary, examining the technique and detection rate. A systematic search of the literature was performed using PubMed and Embase from June 1991 to February 2019. Studies describing the sentinel lymph node technique and lymphatic drainage of the ovaries were incorporated in this review. Ten articles were selected, comprising a total of 145 patients. A variety of agents were used, but the primary markers were technetium-99m radiocolloid (Tc-99m), patent blue, or indocyanine green, and the most common injection site was the ovarian ligaments. The overall sentinel lymph node detection rate was 90.3%. We propose a standardized technique sentinel lymph node mapping in ovarian cancer, using indocyanine green, or Tc-99m and blue dye as alternative tracers, injected in both the suspensory and the infundibulopelvic ligament of the ovary.

Original languageEnglish
Pages (from-to)1209-1215
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume29
Issue number7
DOIs
Publication statusPublished - Sep 2019

Keywords

  • ovarian cancer
  • sentinel lymph node
  • ENDOMETRIAL CANCER
  • LYMPHADENECTOMY
  • METASTASIS
  • IDENTIFICATION
  • MULTICENTER
  • CARCINOMA
  • BIOPSY
  • TRIAL

Cite this